Regulatory Hurdle For Innate Pharma's Blood Cancer Studies

The FDA has placed a clinical hold on Innate Pharma SA's IPHA lacutamab Investigational New Drug (IND), leading to a pause in new patient enrollment in ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102 (Phase 1b PTCL). 

The partial clinical hold follows one fatal hemophagocytic lymphohistiocytosis (HLH), a rare hematologic (blood) disorder. 

Patients already on study treatment who are deriving clinical benefits may continue treatment after being reconsented.

TELLOMAK, Innate Pharma's ongoing Phase 2 trial of lacutamab in cutaneous T-cell lymphoma (CTCL), completed enrollment in Q2 2023 (n=170 patients). 

Enrollment is also completed in the initial cohort (n=20 patients) of the Phase 1b PTCL trial and is awaiting a futility interim analysis to progress to the next stage. 

Innate Pharma is on track for final data from the Phase 2 TELLOMAK trial and preliminary data on PTCL in Q4 2023.

"...Additionally, with all patients recruited into the Phase 2 TELLOMAK study, we do not currently anticipate any delay for the TELLOMAK Phase 2 final data due shortly," commented Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. 

Price Action: IPHA shares are down 9.72% at $2.23 during the premarket session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareFDAMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!